Evidence map›Paper›PMID 29302038›Full record

ArticleNature communications2018

Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss.

Sébastien Lucas, Yasunori Omata, Jörg Hofmann, Martin Böttcher, Aida Iljazovic, Kerstin Sarter, Olivia Albrecht, Oscar Schulz, Brenda Krishnacoumar, Gerhard Krönke and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 474 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
474citing papers in PubMed, 4 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

474 citing papers in PubMed, 4 syntheses or guidelines pooled it, 711 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Gut microbiome and bone health: update on mechanisms, clinical correlations, and possible treatment strategies.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

414 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Sébastien LucasDepartment of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Yasunori OmataDepartment of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Jörg HofmannDivision of Biochemistry, Department of Biology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
Martin BöttcherDepartment of Internal Medicine 5, Hematology and Oncology, Translational Research Center, University Hospital Erlangen, 91054, Erlangen, Germany.
Aida IljazovicHelmholtz Centre for Infection Research, 38124, Braunschweig, Germany.
Kerstin SarterDepartment of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Olivia AlbrechtDepartment of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Oscar SchulzDepartment of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Brenda KrishnacoumarDepartment of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Gerhard KrönkeDepartment of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Martin HerrmannDepartment of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.ORCID http://orcid.org/0000-0002-0258-2484
Dimitrios MougiakakosDepartment of Internal Medicine 5, Hematology and Oncology, Translational Research Center, University Hospital Erlangen, 91054, Erlangen, Germany.
Till StrowigHelmholtz Centre for Infection Research, 38124, Braunschweig, Germany.ORCID http://orcid.org/0000-0003-0185-1459
Georg SchettDepartment of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Mario M ZaissDepartment of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany. mario.zaiss@uk-erlangen.de.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEHelmholtz Centre for Infection Research · DEUniversitätsklinikum Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microbial metabolites are known to modulate immune responses of the host. The main metabolites derived from microbial fermentation of dietary fibers in the intestine, short-chain fatty acids (SCFA), affect local and systemic immune functions. Here we show that SCFA are regulators of osteoclast metabolism and bone mass in vivo. Treatment of mice with SCFA as well as feeding with a high-fiber diet significantly increases bone mass and prevents postmenopausal and inflammation-induced bone loss. The protective effects of SCFA on bone mass are associated with inhibition of osteoclast differentiation and bone resorption in vitro and in vivo, while bone formation is not affected. Mechanistically, propionate (C3) and butyrate (C4) induce metabolic reprogramming of osteoclasts resulting in enhanced glycolysis at the expense of oxidative phosphorylation, thereby downregulating essential osteoclast genes such as TRAF6 and NFATc1. In summary, these data identify SCFA as potent regulators of osteoclast metabolism and bone homeostasis.

Indexed as

AnimalsBone and BonesBone DensityBone ResorptionButyratesDietary FiberFatty Acids, VolatileFemaleGene ExpressionGlycolysisHumansMice, Inbred C57BLOsteoclastsPropionatesProtective AgentsButyratesDietary FiberFatty Acids, VolatilePropionatesProtective Agents

Identifiers

PMID29302038
PMCPMC5754356
OpenAlexW2778082937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.